Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Arsenic trioxide (ATO) is a first-line treatment for acute promyelocytic leukemia.
• ATO exhibits anti-cancer properties against various neoplastic diseases.
• Clinical application of ATO for solid tumors is restricted due to systemic toxicity, low bioavailability, and rapid elimination.

Purpose of the Study:

• To review the medical applications, anti-cancer mechanisms, and limitations of ATO.
• To explore the potential of nanotechnology in delivering ATO to solid tumors.
• To summarize outcomes of ATO in combination therapy and recommend future research.

Main Methods:

• Review of existing literature on ATO's medical applications and anti-cancer mechanisms.
• Analysis of studies investigating nanomedicine approaches for ATO delivery.
• Summary of combinatorial treatments involving ATO and chemotherapy agents.

Main Results:

• Nanomedicines offer advantages like increased bioavailability, effectiveness, and targeted delivery for drugs.
• Nanotechnology-based delivery systems can potentially overcome ATO's limitations for solid tumors.
• Combinatorial treatments with ATO show varied outcomes, highlighting the need for optimized delivery.

Conclusions:

• Nanotechnology holds significant potential for improving ATO's efficacy and safety in treating solid tumors.
• Further pre-clinical and clinical studies of nano-system-based ATO are strongly recommended.
• Nano-system-based ATO could lead to novel, highly effective, and less toxic cancer combination therapies.